History

1999 Feb. Japan Tissue Engineering Co., Ltd established as a joint venture. Operations begun at Hama-cho, Gamagori.
Sep. Relocated the head office to Miyakidadori, Gamagori.
2000 Nov. Awarded the Chubu Bureau of International Trade and Industry Prize in the New Business Awards Division of the Chubu New Business Awards, sponsored by the Chubu New Business Association.
Dec. Submitted application for government approval prior to a clinical trial of Autologous Cultured Epidermis.
2001 Sept. Submitted application for government approval prior to a clinical trial of Autologous Cultured Cartilage.
2002 Jan. Awarded a Special Incentive Award in the 15th Chunichi Industrial Technology Awards sponsored by the Chunichi Shimbun newspaper.
Mar. Obtained authorization to begin clinical trials of autologous cultured epidermis.
2003 Aug. Full-scale entry into cornea cultivation in collaboration with an Italian eye bank (The Veneto Eye Bank Foundation).
Sep. Started multicenter clinical trials of autologous cultured epidermis.
2004 Feb. Obtained authorization to begin clinical trials of autologous cultured cartilage.
May. Started multicenter clinical trials of autologous cultured cartilage.
Jun. Awarded President of the Science Council of Japan's Award at the 16th Awards for Excellence in Collaboration Between Industry, Academia, and Government.
Oct. Submitted application for manufacturing and sales approval of Autologous Cultured Epidermis.
Nov. Completed construction of new premises and moved in.
2005 Mar. Launched sales of LabCyte EPI-MODEL, a cultured human tissue for research use.
Oct. Awarded the Japan Bioventure Grand Prize, the top honor in the Fourth Japan Bioventure Grand Prize awards.
2006 Nov. Awarded the highest prize in the New Business Awards 2006, sponsored by the Chubu Economic Federation.
2007 Mar. Submitted clinical trial completion notification of Autologous Cultured Cartilage.
May. Submitted application for government approval prior to a clinical trial of Autologous Cultured Corneal Epithelium.
Aug. Developed Cell-Culture Kit for research use.
Oct. Received government approval to culture and sell Autologous Cultured Epidermis JACE® for serious burns treatment in Japan.
Dec. Joined the JASDAQ Securities Exchange's Neo market on December 21.
2008 May. Entered into an Advisory Agreement with Prof. Howard Green of Harverd Medical School.
2009 Jan. Autologous Cultured Epidermis JACE®: Listed as an item covered by the National Health Insurance in Japan.
Aug. Submitted application for manufacturing and sales of Autologous Cultured Cartilage.
2010 Jul. Launched sales of LabCyte CORNEA-MODEL, a cultured human tissue for research use.
Oct. Issued new shares by third party allocation. The largest shareholder in J-TEC changed from NIDEK Co., Ltd. to FUJIFILM Corporation.
2011 Mar. Autologous Cultured Epidermis JACE®: Designated as an orphan medical device for epidermolysis bullosa.
2012 May Started a clinical trial of Autologous Cultured Epidermis JACE for epidermolysis bullosa.
Jul. Received Government Approval to Manufacture and Sell Autologous Cultured Cartilage JACC® in Japan
2013 Apr. Autologous Cultured Cartilage JACC®: Listed as an item covered by the National Health Insurance in Japan.
Sep. Awarded the 5th MONOZUKURI Manufacturing Japan Grand Awards: Prime Minister's Prize.
2014 Jan. Started a clinical trial of Autologous Cultured Epidermis JACE for giant nevi.
Jan. Awarded the 2013 Nikkei Superior Products and Services Awards: Nikkei Awards for Excellence.
Aug. Awarded the 12th Award for Persons of Merit in Industry-Academia-Government Collaboration (Minister of Health, Labour and Welfare Prize).
Oct. Started multicenter clinical trials of autologous cultured corneal epithelium.
Nov. Autologous Cultured Epidermis JACE®: Designated as an orphan regenerative medical product for giant nevi.
Nov. Started consulting and contract cell processing business for medical institutions.
Dec. Fujifilm Holdings Corporation became a parent company of J-TEC.
2015 Mar. Autologous Cultured Corneal Epithelium: Designated as an orphan regenerative medical product for corneal stem cell damage.
Oct. Received government approval as a center for contract cell processing.
2016 Jan. Autologous Cultured Epidermis "JACE" : Submitted supplemental application for Giant Nevi.
Apr. Started the Contract Development, Research, and Manufacturing Organization business specialized in regenerative medicine.
Sep. Received government approval to culture and sell Autologous Cultured Epidermis JACE® for Giant Nevi in Japan.
Dec. Autologous Cultured Epidermis JACE® for Giant Nevi: Listed as an item covered by the National Health Insurance in Japan.
2017 Jun. Autologous Cultured Epidermis JACE®: End of re-examination period.
2018 Mar. Autologous Cultured Epidermis JACE®: Submitted supplemental application for Epidermolysis Bullosa.
Apr. Autologous Cultured Cartilage JACC®: Submitted supplemental application for a simplified, minimally invasive transplant procedure.
Jun. Entered into a patent license agreement with Nagoya University, and Shinshu University for the development of a low-cost manufacturing technology for autologous CAR-T cell therapy with enhanced targeting efficiency against CD 19-positive acute lymphoblastic leukemia.
Jul. Submission of CTN for Clinical Trial of Autologous Cultured Epidermis with Melanocyte, "ACE02" for the Treatment of Leukoderma.
Jul. Eye Irritancy Testing Method using "LabCyte CORNEA-MODEL24" Human 3-Dimensional Cultured Corneal Epithelium Included in OECD Test Guideline.
Jul. Autologous Cultured Cartilage JACC®: Submitted CTN for Clinical Trial of Include Secondary Knee Osteoarthritis from Trauma.
Sept. Fujifilm Corporation became a parent company of J-TEC.
Dec. Received government approval to culture and sell Autologous Cultured Epidermis JACE for Epidermolysis Bullosa in Japan.
2019 Jan. Autologous Cultured Cartilage JACC: Received government approval for a simplified, minimally invasive transplant procedure.
Mar. Submitted application for manufacturing and sales of Autologous Cultured Corneal Epithelium in Japan.
Apr. Received the "Science and Technology Award" from the Minister of Education, Culture, Sports, Science and Technology in the field of science and technology in 2019 for "development of autologous cultured epidermis."
Jun. Skin Corrosion Testing Method using "LabCyte EPI-MODEL24" Human 3-Dimensional Cultured Epidermis Included in OECD Test Guideline.
Jul. Autologous Cultured Epidermis JACE for Epidermolysis Bullosa: Listed as an item covered by the National Health Insurance in Japan.
Sept. Started manufacturing and sales of F-hiSIEC (FUJIFILM human iPS cell-derived Small Intestinal Epithelial like Cell).
2020 Mar. Received government approval to culture and sell Autologous Cultured Corneal Epithelium Nepic for corneal epithelial stem cell deficiency in Japan.
Jun. Autologous Cultured Corneal Epithelium Nepic: Listed as an item covered by the National Health Insurance in Japan.
Sept. Submitted application for manufacturing and sales of Autologous Cultured Oral Mucosal Epithelium in Japan.
2021 Mar. The parent company and the largest shareholder in J-TEC changed from FUJIFILM Corporation to TEIJIN LIMITED.